A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2017-03-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, placebo-controlled, multiple-ascending dose (MAD) study that will evaluate the safety, tolerability and pharmacokinetics (PK) of RO7079901 and the combination of RO7079901 with meropenem in healthy volunteers. The study will consist of three parts (Part I, II, and III). At each dose level/cohort, a total of 8 healthy volunteers will be randomized to receive active study drug or placebo in a 3:1 ratio.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection

NCT03174795

Urinary Tract Infections

COMPLETED PHASE1

A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants

NCT03182504

Gram-negative Bacterial Infections

COMPLETED PHASE1

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects

NCT01897779

Healthy Volunteers Bacterial Infections

COMPLETED PHASE1

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections

NCT07089186

Hospital-acquired Bacterial Pneumonia (HABP) Ventilator-associated Bacterial Pneumonia (VABP) Complicated Intra-abdominal Infection (cIAI) +2 more

RECRUITING PHASE3

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects

NCT01702649

Healthy Volunteers Bacterial Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part I: RO7079901

Participants will be randomized in two dose cohorts to receive single dose of RO7079901 1000 and 2000 milligrams (mg) intravenous (IV) infusion on Days 1 through Day 7 every 8 hours (q8h), for a total of 19 doses, with the last dose administered on the morning of Day 7.

Group Type EXPERIMENTAL

RO7079901

Intervention Type DRUG

RO7079901 will be administered as per schedule described in individual arm.

Part I: Placebo

Participants will be randomized in two dose cohorts to receive single dose of placebo matching to RO7079901 on Days 1 through Day 7 q8h, for a total of 19 doses, with the last dose administered on the morning of Day 7.

Group Type PLACEBO_COMPARATOR

RO7049389 Placebo

Intervention Type OTHER

Placebo matching to RO7049389 will be administered as per schedule described in individual arm.

Part II - Single Dose and Repeat Dose: RO7079901

Participants will be randomized in two dose cohorts to receive single dose of RO7079901 IV infusion at a dose above the previously studied dose levels in Part I (greater than \[\>\] 2000 mg) on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.

Group Type EXPERIMENTAL

RO7079901

Intervention Type DRUG

RO7079901 will be administered as per schedule described in individual arm.

Part II - Single Dose and Repeat Dose: Placebo

Participants will be randomized in two dose cohorts to receive single dose placebo matching to RO7079901 on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.

Group Type PLACEBO_COMPARATOR

RO7049389 Placebo

Intervention Type OTHER

Placebo matching to RO7049389 will be administered as per schedule described in individual arm.

Part III: RO7079901 + Meropenem

Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem IV infusion in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of 2000 mg meropenem IV infusion on Day 1. On Day 2, participants will receive a single dose of RO7079901 IV infusion. Participants randomized to Sequence 2 will receive a single dose of RO7079901 IV infusion on Day 1. On Day 2, participants will receive a single dose of 2000 mg meropenem IV infusion. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 in combination with meropenem IV infusion q8h, regardless of sequence. Escalation to a maximum dose of RO7079901 5000 mg q8h may be considered on the basis of safety and tolerability data from the previous cohorts.

Group Type EXPERIMENTAL

RO7079901

Intervention Type DRUG

RO7079901 will be administered as per schedule described in individual arm.

Meropenem

Intervention Type DRUG

Meropenem will be administered as per schedule described in individual arm.

Part III: RO7079901 Placebo + Meropenem Placebo

Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem matching placebos in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of placebo matching to meropenem on Day 1. On Day 2, participants will receive a single dose of placebo matching to RO7079901. Participants randomized to Sequence 2 will receive a single dose of placebo matching to RO7079901 on Day 1. On Day 2, participants will receive a single dose of placebo matching to meropenem. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 and meropenem matching placebos q8h, regardless of sequence.

Group Type PLACEBO_COMPARATOR

RO7049389 Placebo

Intervention Type OTHER

Placebo matching to RO7049389 will be administered as per schedule described in individual arm.

Meropenem Placebo

Intervention Type OTHER

Placebo matching to meropenem will be administered as per schedule described in individual arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RO7079901

RO7079901 will be administered as per schedule described in individual arm.

Intervention Type DRUG

Meropenem

Meropenem will be administered as per schedule described in individual arm.

Intervention Type DRUG

RO7049389 Placebo

Placebo matching to RO7049389 will be administered as per schedule described in individual arm.

Intervention Type OTHER

Meropenem Placebo

Placebo matching to meropenem will be administered as per schedule described in individual arm.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male or healthy female of non-childbearing-potential
* A Body Mass Index (BMI) between 18.0 and 30.0 kilograms per square meter (kg/m\^2) (inclusive) and a body weight of at least 45 kilograms (kg) at screening
* Negative urine drug and alcohol screen (barbiturates, benzodiazepines, methadone, amphetamines, methamphetamines, opiates, cocaine, cannabinoids, cotinine, and alcohol)
* Non-smokers, or former smokers, who have not smoked for at least 60 days prior to screening

Exclusion Criteria

* Known history of any significant hypersensitivity or severe allergic reaction to any beta-lactam antibiotics (e.g., cephalosporins, penicillins, carbapenems, or monobactams)
* History of any severe antibiotic-associated superinfections like Clostridium difficile colitis and/or frequent fungal vaginal infections
* Concurrent or history of clinically significant cardiovascular, hepatic, renal, endocrine, gastrointestinal, respiratory, psychiatric, neurologic, and/or hematological disorders
* A history or presence of malignancy (with the exception of successfully treated basal cell carcinoma); seizures, brain lesions or other significant neurological diseases
* Donation of blood (or loss of blood) greater than 500 milliliters (mL) within three months before screening
* History of Gilbert syndrome
* Any clinically significant concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the healthy volunteer in this study
* Positive test at screening of any of the following: Hepatitis A Virus Immunoglobulin M Antibody (HAV IgM Ab), Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus Ribonucleic Acid or Hepatitis C Virus Antibody (HCV RNA or HCVAb), or Human Immunodeficiency Virus Antibody (HIV Ab)

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes